Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NT 219

Next Previous
Drug Profile

NT 219

Alternative Names: NT-219

Latest Information Update: 19 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hebrew University of Jerusalem
  • Developer Purple Biotech; TyrNovo
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Insulin receptor substrate protein inhibitors; STAT3 transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Colorectal cancer; Solid tumours; Squamous cell cancer
  • Preclinical Malignant melanoma

Most Recent Events

  • 19 Apr 2024 Purple Biotech plans a phase II trial in Squamous cell cancer and Colorectal cancer (Recurrent, Metastatic disease, Combination therapy) in the first half of 2024 (Purple Biotech pipeline, April 2024)
  • 27 Feb 2024 Updated efficacy, adverse events and pharmacokinetics data from a phase I/II trial in Squamous cell cancer, Solid tumours and Colorectal cancer presented at the European Society of Medical Oncology Targeted Anticancer Therapies Congress 2024 (ESMO TAT-2024)
  • 26 Feb 2024 Efficacy, adverse events and pharmacokinetics data from a phase I/II trial in Squamous cell cancer presented at the European Society of Medical Oncology Targeted Anticancer Therapies Congress 2024 (ESMO TAT-2024)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top